foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}

Rituximab tedavisinin etkisi

Translated title of the contribution: Incidence of non-neutropenic infection (NNI) in patients with follicular lymphoma and small lymphocytic lymphoma: The effects of rituximab therapy

Rezwan Islam, Mahbubur Rahman, M. Anwarul Huq Mian, Hilmi Ege, Douglas Reding, Md Abdus Shakoor, Hong Liang, Richard Mercier

    Research output: Contribution to journalArticle

    Abstract

    Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin's lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to non-rituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.

    Original languageUndefined
    Pages (from-to)220-226
    Number of pages7
    JournalUHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
    Volume22
    Issue number4
    DOIs
    StatePublished - 2012

    Fingerprint

    Follicular Lymphoma
    B-Cell Chronic Lymphocytic Leukemia
    Incidence
    Infection
    Therapeutics
    Rituximab
    Non-Hodgkin's Lymphoma
    Medical Records
    B-Lymphocytes
    Monoclonal Antibodies
    Regression Analysis

    Keywords

    • Follicular lymphoma
    • Incidence
    • Infection
    • Rituximab
    • Small lymphocytic lymphoma

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Cite this

    foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless} : Rituximab tedavisinin etkisi. / Islam, Rezwan; Rahman, Mahbubur; Anwarul Huq Mian, M.; Ege, Hilmi; Reding, Douglas; Shakoor, Md Abdus; Liang, Hong; Mercier, Richard.

    In: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, Vol. 22, No. 4, 2012, p. 220-226.

    Research output: Contribution to journalArticle

    Islam, Rezwan ; Rahman, Mahbubur ; Anwarul Huq Mian, M. ; Ege, Hilmi ; Reding, Douglas ; Shakoor, Md Abdus ; Liang, Hong ; Mercier, Richard. / foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless} : Rituximab tedavisinin etkisi. In: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi. 2012 ; Vol. 22, No. 4. pp. 220-226.
    @article{11ffeda00d594bbdbae4ffd042fe9558,
    title = "folik{\"u}ler lenfomali{dotless} ve k{\"u}{\cc}{\"u}k lenfositik lenfomali{dotless} hastalarda n{\"o}tropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi",
    abstract = "Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin's lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to non-rituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.",
    keywords = "Follicular lymphoma, Incidence, Infection, Rituximab, Small lymphocytic lymphoma",
    author = "Rezwan Islam and Mahbubur Rahman and {Anwarul Huq Mian}, M. and Hilmi Ege and Douglas Reding and Shakoor, {Md Abdus} and Hong Liang and Richard Mercier",
    year = "2012",
    doi = "10.4999/uhod.11035",
    language = "Undefined",
    volume = "22",
    pages = "220--226",
    journal = "UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi",
    issn = "1306-133X",
    publisher = "UHOD - Uluslararasi Hematoloji Onkoloji Dergisi",
    number = "4",

    }

    TY - JOUR

    T1 - foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}

    T2 - Rituximab tedavisinin etkisi

    AU - Islam, Rezwan

    AU - Rahman, Mahbubur

    AU - Anwarul Huq Mian, M.

    AU - Ege, Hilmi

    AU - Reding, Douglas

    AU - Shakoor, Md Abdus

    AU - Liang, Hong

    AU - Mercier, Richard

    PY - 2012

    Y1 - 2012

    N2 - Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin's lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to non-rituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.

    AB - Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin's lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to non-rituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.

    KW - Follicular lymphoma

    KW - Incidence

    KW - Infection

    KW - Rituximab

    KW - Small lymphocytic lymphoma

    UR - http://www.scopus.com/inward/record.url?scp=84871633694&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84871633694&partnerID=8YFLogxK

    U2 - 10.4999/uhod.11035

    DO - 10.4999/uhod.11035

    M3 - Article

    VL - 22

    SP - 220

    EP - 226

    JO - UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

    JF - UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

    SN - 1306-133X

    IS - 4

    ER -